ImmunoGen, Inc. (NASDAQ:IMGN) Q3 2022 Earnings Conference Call November 4, 2022 8:00 AM ET
Company Participants
Anabel Chan - Head, Investor Relations
Mark Enyedy - President, CEO & Director
Anna Berkenblit - SVP & Chief Medical Officer
Susan Altschuller - SVP & CFO
Conference Call Participants
John Newman - Canaccord Genuity
Michael Schmidt - Guggenheim Securities
Etzer Darout - BMO Capital Markets
Faisal Khurshid - SVB Securities
Andy Hsieh - William Blair & Company
Peter Lawson - Barclays Bank
Arthur He - H.C. Wainwright & Co.
Boris Peaker - Cowen and Company
Kelly Shi - Jefferies
Daniel Wolle - JPMorgan Chase & Co.
Operator
Good morning, and welcome to ImmunoGen's Third Quarter 2022 Financial and Operating Results Conference Call. Today's conference is being recorded.
At this time, I'd like to turn the call over to Anabel Chan, Head of Investor Relations. Please go ahead.
Anabel Chan
Good morning, and thank you for joining today's call. Earlier today, we issued a press release that includes a summary of our recent operating progress and third quarter 2022 financial results. This press release, a recording of this call and an updated corporate deck can be found under the Investors and Media section of our website at immunogen.com.
With me today are Mark Enyedy, our President and CEO; Anna Berkenblit, our Chief Medical Officer; and Susan Altschuller, CFO. During today's call, we will review recent accomplishments for the business, our Q3 financial results and highlight upcoming anticipated events.
We will be making forward-looking statements based on our current expectations and beliefs. These statements are subject to risks and uncertainties, and our actual results may differ materially. Please consult the risks outlined in our press release issued this morning. In the Risk Factors section of our most recent annual report on Form 10-K and quarterly report on Form 10-Q and in our other SEC filings, which are available at sec.gov and immunogen.com.
With that, I'll turn the call over to Mark.
Mark Enyedy
Good morning, and thank you for joining us today. With approval expected on or before our November 28 PDUFA date, we've taken the last quarter to complete our preparations to launch mirvetuximab this month. Just to put a finer point on these activities, our highly experienced field team is fully staffed and out engaging with customers. Our distribution, market access and patient support infrastructure is in place and we have vials of commercial-ready drug product and inventory awaiting labeling and packaging.